Researchers have found that adding low-dose ibuprofen to the usual allergy relief treatment of chlorpheniramine and pseudoephedrine improves relief from seasonal allergic rhinitis. The findings from the 7-day trial were presented recently at the American College of Allergy, Asthma and Immunology Annual Meeting.
For the study, the investigators randomized patients to a placebo or to treatment in a double-blind, double-dummy, parallel-group fashion. The participants had at least a 2-year history of seasonal allergic rhinitis. The first group (n = 265) received a triple combination of ibuprofen, pseudoephedrine, and chlorpheniramine. In the first arm of the triple combination group, participants received 200 mg ibuprofen, 30 mg pseudoephedrine, and 2 mg chlorpheniramine. Participants in the second arm received 400 mg ibuprofen, 60 mg pseudoephedrine, and 4 mg chlorpheniramine. The second group (n = 266) received 30 mg pseudoephedrine and 2 mg chlorpheniramine without ibuprofen. The third group (n = 257) received a placebo.
The participants were asked to assess 6 allergy-associated symptoms on a 4-point severity scale with assessments made every other day. The results showed that, in both arms of group 1, pain was decreased 40% more, compared with the placebo group, and 33% more in the pseudoephedrinechlorpheniramine group. When ibuprofen was added to chlorpheniramine and pseudoephedrine, the researchers saw an increase in pain relief that ranged from 33% to 34%. The increases in other allergy symptoms ranged from 19% to 22%, compared with the standard combination.
While many states across our nation are engaged in political battles over the recreational use of marijuana, researchers have been busy studying the medical benefits of cannabidiol.
News from the year's biggest meetings
Clinical features with downloadable PDFs